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Abstract  
Introduction: Measurement of bone turnover markers (BTMs) may be useful to monitor offset of treatment with 
bisphosphonates (BP) in osteoporosis.  We assessed the effect of withdrawal of BP treatment by comparing the 
changes in BTMs and total hip (TH) bone density (BMD).  
Methods: We studied postmenopausal osteoporotic women who had completed a randomized study of 3 oral 
BPs.  After 2 years of treatment, participants with BMD T-score >-2.5 and in whom it was considered clinically 
appropriate to discontinue treatment, were invited to participate in a further 2-year observational study.  
Biochemical response was assessed using BTMs (CTX and PINP) with offset being defined by two criteria, 1) 
an increase greater than the least significant change (LSC), 2) an increase above the reference mean value.  
Results: Fifty women completed the study. At 48 weeks after stopping BPs, CTX was greater than the LSC for 
66% of women and PINP 72%, CTX was above the reference mean for 64% of women and PINP 42%.  The 
decrease in THBMD was greater for women with the largest increase in BTM compared to those with continued 
suppression (mean difference for CTX was -2.98%, 95%CI -4.75 to -1.22, P<0.001, PINP -2.25%, 95% CI -4.46 
to -0.032, P=0.046).     
Conclusion: The measurement of BTM after withdrawal of BPs is potentially useful to evaluate patients that are 
taking a pause from treatment.  An increase in BTMs more than the LSC and/or reference mean reflects loss of 
treatment effect and identifies patients that are likely to have a decrease in BMD.  Such changes could provide 
an indication for reintroduction of treatment.    
 
 
Keywords: bone markers, bone density, bisphosphonate, osteoporosis 
 
Mini abstract:  
Bone markers may be useful to monitor response to treatment withdrawal in osteoporosis. We used 2 criteria for 
investigating the change in BTMs after withdrawal of bisphosphonate treatment.  A larger increase in BTMs 
was associated with greater bone loss.  Bone markers may be useful in monitoring of patients taking a pause 
from treatment.  
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Introduction 
Oral bisphosphonates (BPs) are widely used for the treatment of postmenopausal osteoporosis [1].  The 
beneficial effects may persist after treatment is withdrawn due to the retention of BPs in bone [2-4], and it has 
been suggested that patients who are not at high risk of fracture may be considered for a pause in BP treatment 
[5].  When bisphosphonate treatment is interrupted, it is important to periodically review the patient to monitor 
for indications for recommencing treatment.   Clinical assessment usually includes measurements of BMD, but 
BTMs may be a useful adjunct for management [6].  Indeed, the International Osteoporosis Foundation (IOF) 
and International Federation of Clinical Chemistry (IFCC) have recommended the use of reference standard 
BTMs [7, 8], which have been shown to decrease significantly after commencement of anti-resorptive therapies 
as a means to identify a response to treatment; the corollary suggests that it would be reasonable to consider that 
an increase in BTMs after treatment has been stopped may be useful to monitor offset of effect in patients [9].  
Certainly, when BP treatment is withdrawn there is an increase in bone turnover markers (BTMs) and a decrease 
in bone mineral density (BMD) [10, 11], but little is known about their utility in clinical management.    
 
We have previously reported the changes in BTM and BMD in a randomized trial of 3 oral BPs during and after 
withdrawal of treatment [12-14]. The criteria to define a clinically meaningful change or response in BTMs are 
not standardised, but two approaches can be used; firstly, a response can be assumed if the BTM changes from 
baseline by an amount that is greater than the least significant change (LSC), or the value on treatment can be 
compared to the reference interval, with response constituting a value that lies below the reference mean (for 
healthy young women) [7].  Similar approaches might be taken to define offset of the effect of treatment.  In this 
analysis, we have investigated the relationship between changes in BTMs and BMD following withdrawal of BP 
treatment, to see if this could provide clinically applicable information for clinicians managing individual 
patients.   
 
 
Methods 
Study Design 
The study comprised a 2-year, open-label, parallel, randomised controlled intervention trial of 3 oral BPs (TRIO 
study) [12, 13]. At the end of the treatment study, eligible participants were invited to participate in an 
observational extension study for a further 2-years with no treatment (TRIO offset study) [14].    
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Study Population 
The TRIO study recruited women with postmenopausal osteoporosis defined by dual-energy x-ray 
absorptiometry (DXA) at the lumbar spine or proximal femur as i) a BMD T score <-2.5 or ii) a BMD T score 
<-1.0 plus a prevalent non-traumatic fracture.  The recruitment details have been described previously [12].  
Participants were randomised to receive one of three oral BPs at the licensed dose for 2 years: (i) ibandronate 
(Bonviva, Roche, 150mg), (ii) alendronate (Fosamax, Merck, 70 mg), or (iii) risedronate (Actonel, Warner-
Chilcott, 35 mg) [12] and also received calcium carbonate 3g (1200 mg elemental calcium) and cholecalciferol 
20 micrograms (800 IU) per day (Adcal D3, ProStrakan), initiated one week before commencement of 
treatment.  The study, approved by the Sheffield Research Ethics Committee and the Medicines and Healthcare 
Products Regulatory Agency (MHRA), was carried out in accordance with the Declaration of Helsinki and the 
International Conference on Harmonisation Good Clinical Practice (ICH GCP) guidelines.  Written informed 
consent was obtained for all participants.  At the end of the 2-year treatment study, women with hip BMD T-
score >-2.5 and in whom it was considered clinically appropriate to pause treatment (n=57), were invited to 
participate in a further 2-year observational study.  The criteria for invitation and subsequent inclusion in this 
TRIO Offset study have been published [14].  
Study Outcomes and Assessments 
The total study was conducted over 192 weeks with visits at baseline 1 (week -1), baseline 2 (week 0, 
randomization and commencement of BP), then at 12, 48 and 96 weeks (TRIO study), then after withdrawal of 
BP at 24, 48, 72 and 96 weeks (TRIO offset study).  Fasting blood was collected (left to clot for 30 minutes, 
centrifuged at 2500g for 10 minutes) and stored at -80¡C until analysis.  The C-telopeptide of type I collagen 
(CTX) and intact pro-collagen I N-propeptide (PINP) were measured using the IDS-iSYS (Immunodiagnostic 
Systems, Boldon, UK), inter-assay CV 4.4% and 4.5% respectively.  
BMD (g/cm
2
) of the total hip (TH) was measured by DXA (Discovery A densitometer, Hologic Inc, Bedford, 
MA) at baseline and weeks 12 and 96 on treatment, then at week 48 and 96 off treatment, (visit window + 2 
weeks).   
Definition of BTM offset 
The sample size for the TRIO offset study was constrained by the proportion of eligible patients from the 
original TRIO study [14].  Change in BTMs after withdrawal of treatment was classified according to 2 criteria, 
namely increases greater than the LSC and values rising to above the reference mean.  
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LSC 
The least significant change (LSC) was calculated using measurements from the 12 and 13 week visits of the 
treatment group (n=147) as follows: 
���!=!Z
'
 ! 2 !!SDRMS 
 
where SDRMS is the root-mean-square standard deviation calculated from the data, and Z' is equal to 1.96 for 
95% confidence level.  Participants in whom the 48 week BTM measurement in the TRIO offset study showed 
increases greater than the LSC from the baseline value at entry to the TRIO offset study were defined as having 
treatment offset.  The LSC for PINP was 10 µg/L, while for CTX the LSC was 160 ng/L. 
Reference mean 
The reference mean value was calculated from 20 premenopausal women (geometric mean, 95% CI) who had 
participated as controls in the TRIO study.  Participants in whom the BTM measurement at 48 weeks in the 
TRIO offset study lay above the premenopausal mean were defined as having treatment offset.  The 
premenopausal means for PINP and CTX were 35 µg/L and 240 ng/L respectively.   
 
Statistical analysis 
Changes in TH BMD, from start of the TRIO Offset study, are presented as least square mean percentage 
changes with two-sided 95% CI.  The change in TH BMD after withdrawal of BP was compared by analysis of 
covariance (ANCOVA) with Bonferroni correction, adjusted for THBMD at baseline (end of treatment), in 3 
groups for each of the BTMs; those showing offset by both a greater than LSC increase and a value lying above 
the threshold mean offset, those showing partial offset by only one of these criteria, and finally those showing 
neither of these criteria (no offset).  The change in TH BMD was compared between those above or below the 
mean and greater than or less than LSC for each BTM (ANCOVA with Bonferroni correction).   CohenÕs kappa 
coefficient was used to test for concordance between offset category as defined by LSC and reference mean 
criteria within and between the BTMs. The relationship between the change in BTMs at 48 weeks off treatment, 
and percentage change in THBMD was investigated using PearsonÕs correlation.  Baseline BTMs were 
compared between the 3 responder groups by Kruskal Wallis analysis.  Statistical analyses were conducted 
using Stata statistical software (StataCorp. 2015 Stata Statistical Software: Release 14. College Station, TX: 
StataCorp LP.), and MedCalc Statistical Software version 14.10.2 (MedCalc Software bvba, Ostend, Belgium; 
http://www.medcalc.org; 2014).  
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Results   
Baseline Characteristics 
From the original TRIO study, 94 participants were assessed for eligibility and 59 consented to continue into the 
TRIO offset study, with 2 subsequently withdrawing before the start of the study.  The baseline characteristics 
of those that entered the TRIO offset study compared to those who did not participate have been published 
previously [14].    In summary, at the TRIO baseline, the participants in the TRIO offset study (n=57) were 
similar to all participants in the TRIO study in terms of mean age (66.6 vs. 65.9 years, P=0.67) and mean BMI 
(26.1 vs 25.1kg/m
2
, P=0.97) but, given the selection criteria for the Offset study, had higher TH BMD at both 
TRIO baseline (T-score -1.14 vs -1.70, P=0.006) and at the end of TRIO (T-score -0.9 vs -1.6, P=0.006).  Of the 
57 women recruited from the TRIO study, 18 had been allocated ibandronate, 21 alendronate and 18 risedronate 
[14].  
 
Bone Turnover Markers 
 
Of the 57 women entering TRIO Offset, BTM data were available for 50 of them at 48 weeks after stopping BP.  
The increase in CTX was by more than the LSC for 33 women (66%) (Figure 1A) and was above the reference 
mean for 32 women (64%) (Figure 1B), with 29 women (58%) showing changes in both measurements, 7 
women (14%) showing changes in only one and 14 women (28%) in neither.  The increase in PINP was by more 
than the LSC for 36 women (72%) (Figure 1A) and was above the mean for 21 (42%) (Figure 1B), with 18 
women (36%) having both changes, 21 women (42%) showing changes in only one parameter and 12 women 
(24%) neither parameter. Within the markers, there was good concordance between classification of offset by 
the LSC and mean parameters for CTX (Kappa 0.69) but not with PINP (Kappa 0.22).  Between markers, there 
was good concordance between CTX and PINP classification using the LSC method (Kappa 0.49) and the mean 
threshold approach (Kappa 0.58).    
The time course of changes in BTM over the study period for those classified as showing offset, partial offset or 
no offset is shown in Supplemental Figure 2.  For both PINP and CTX, the women with offset (i.e fulfilling both 
LSC and mean parameters) had significantly higher BTMs prior to bisphosphonate treatment at entry to the 
TRIO study than those showing offset by only one criterion or not showing offset.  For example, the median 
(IQR) value of serum PINP in those showing offset was 63.6μg/L (53.4 to 81.1, n=18) compared to 49.2μg/L 
(95% CI 40.6 to 55.9, n=21) and 51.6μg/L (37.2 to 57.1, n=11) in those with partial or no offset respectively 
(p<0.05).  For CTX, the baseline median value was 580ng/L (405 to 742, n=29) in those showing offset 
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compared to 310 ng/L (230 to 430, n=14) in those without offset, while women showing a partial offset had 
intermediate values (430 ng/L, 300 to 528, n=7) (P<0.05 between the groups).     
Bone Mineral Density 
The changes in BMD during treatment have been previously published [12].  We compared the change in TH 
BMD over 96 weeks off treatment in the 3 groups classified by BTM change after withdrawal of treatment at 48 
weeks after stopping treatment (data were available for 49 women).  At the end of the 2 year discontinuation 
period, only one participant had a BMD T-score of <-2.5.  Total hip BMD loss was significantly greater in those 
women showing BTM offset (a change in BTMs greater than the LSC and above the mean value at week 48 
after stopping treatment) compared to those who only met one threshold (partial offset) or neither (Table 1).  
There was a significant difference in the TH BMD percentage change for those with offset by both criteria (LSC 
and reference mean) for CTX or PINP compared to those with neither criteria met (-2.98%, P<0.001, -2.25%, 
P=0.046 respectively) but no significant difference to those with neither criteria met, (either greater than LSC or 
the mean).  
The participants with the greatest increase in BTMs at 48 weeks after stopping treatment had the largest 
decrease in TH BMD 96 weeks after stopping treatment CTX r=-0.58 (95% CI -0.74 to -0.36) P<0.001, PINP 
r=-0.41 (95% CI -0.62 to -0.14) P<0.005.  
 
 
 
Discussion  
BTMs have been used in clinical research for many years but their uptake in clinical practice varies widely.  
One of the limitations to more widespread use is the relatively poor reproducibility of BTM, which can be 
addressed by adopting standardized sample handling and patient preparation procedures [15].  We assessed the 
change in BTM after the withdrawal of BP treatment using 2 criteria as suggested by the IOF and IFCC to 
monitor treatment of osteoporosis in postmenopausal women [7].  The values for CTX and PINP LSC and 
reference mean were comparable to those reported by Morris et al [16].  Importantly, the offset of treatment 
effect using criteria for either the resorption marker CTX or the bone formation marker PINP was associated 
with more rapid bone loss at the hip over a two year period.  Specifically, those women showing offset of bone 
turnover suppression by changes in either marker at 48 weeks off treatment, particularly when those changes 
were greater than the LSC, demonstrated greater decreases in hip BMD.  These observations suggest that 
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monitoring of BTM at the earlier time point could prove useful in influencing follow-up and decisions to 
reintroduce treatment. 
Another clinically important observation from our analysis is that women with higher BTM at baseline (prior to 
treatment) had a greater increase and return towards higher turnover during the offset period.  Furthermore, the 
mean percentage decrease in TH BMD during the 2 years off treatment was greater in these women.  These 
findings suggest that those women with high baseline BTM may require earlier assessment of offset to 
determine if there is an indication to restart treatment.  The relationship between high baseline turnover and a 
subsequent return to relatively high turnover has been observed during denosumab treatment [17].  However, 
after withdrawal of denosumab, there is a return to baseline followed by a transient increase in BTM  above 
baseline associated with accelerated bone loss, whereas after BP withdrawal BTM return to baseline and bone 
loss is slower [18]. 
It is important to note that the LSC method used absolute changes as used in clinical practice, rather than 
percentage changes, as the CTX value can be suppressed to zero with BP treatment so would not be a suitable 
baseline for calculation of percentage change during offset.  Where a pre-treatment baseline BTM measurement 
may not be available in clinical practice, a measurement at the end of treatment appears to be an appropriate 
baseline by which to assess the offset of treatment effect.  In the absence of a sample at the end of treatment, 
thus excluding the use of the LSC response, then values that lie above the premenopausal mean at 48 weeks can 
also identify apparent offset of effect, particularly when using CTX. 
 
This study has a number of limitations.  Firstly, the assay used for measurement of BTMs should be taken into 
account, as there are discrepancies between results from different manufacturers [15, 19].  Jorgensen et al found 
a significant disagreement between the IDS-iSYS and Roche Cobas assay for PINP and CTX.   This will 
influence the reference intervals and it is recommended that patients should be monitored with the same assay 
[19].  The National Bone Health Alliance has recommended that standardised sample handling and patient 
preparation procedures are adopted to minimise variability [15].   It is important that the laboratory adheres to 
robust internal and external quality assurance programmes.  
Furthermore, we acknowledge that the 2-year duration of BP treatment is not representative of usual 
recommended clinical practice in postmenopausal osteoporosis, but many patients with poor compliance or 
persistence will withdraw from treatment in relatively short timeframes [20].  The effect of treatment may 
diminish at a different rate after withdrawal of treatment if the women were treated for a more standard 5 years 
with oral BP, but data from the oral risedronate study showed parallel rates of offset at 2 and 7 years [11].  We 
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were not able to consider fracture rates, as the number of subjects is small, but the data on total hip BMD 
suggest that the observed offset is associated with potential clinical consequences.  It is not clear that the use of 
BTMs in the setting of postmenopausal osteoporosis is translatable to offset in other forms of osteoporosis, 
particularly causes of secondary osteoporosis such as glucocorticoid use.  Finally, though allocation to BP was 
randomised, the criteria for discontinuation of treatment may have resulted in a non-random comparison 
amongst those who participated in the TRIO Offset study and does not include the women with more severe 
osteoporosis.   
In conclusion, measurements of CTX and/or PINP appear useful in evaluating the offset of bone turnover 
suppression in patients that are taking a pause from BP treatment.  An increase in BTM by more than LSC 
and/or change to greater than the reference mean predicts loss of BMD and by inference a possible increase in 
fracture risk.  We propose the LSC as the optimal assessment of BTM offset with the comparison to the 
reference interval providing additional information to help clinical management of patients, particularly when 
there is no baseline BTM measurement available.   
It would therefore be reasonable to use this as an indication to consider re-introduction of treatment if the 
individual is at high risk of fracture. Those with continued suppression of BTMs are likely to have stable BMD 
and may remain off treatment with continued monitoring. 
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Figure Legends 
 
Fig 1.  Change in BTM with LSC (A) and absolute value with reference mean (B) for BTM at 48 weeks after 
stopping BP treatment. The LSC and reference mean are shown as dashed lines.   
 
Suppl Fig 2 The time course of changes in BTM during 2 years BP treatment then 2 years off treatment for 
individuals (top panels), mean value with SE (bottom panels) for CTX and PINP.  BTM values at 48 weeks 
(labelled as year 3) after stopping treatment were used to identify a significant change.   Lines shown in red: 
BTM Δ >LSC and BTM> mean, green: BTM Δ >LSC or BTM>mean, black: BTM Δ <LSC and <mean, black 
dash line: premenopausal mean. 
 
Table 1.  
The mean percentage change in total hip BMD during the 2 years after withdrawal of BP treatment for study 
participants with BTM values greater than or less than the LSC or reference mean at 48 weeks offset.   
Comparison of groups by ANCOVA, week 48 offset change in BTM 
1 
both >LSC and >mean, 
2 
change in BTM 
< LSC and <mean, 
3 
either >LSC or >mean (
*
P<0.05, 
**
P< 0.01, 
***
P< 0.001). 
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